Quick Answer
KalVista Pharmaceuticals, Inc. reported Cash and Equivalents of $131.62 million for fiscal year 2025.
KalVista Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $131.62M | +314.0% |
| 2024 | $31.79M | -43.5% |
| 2023 | $56.24M | +83.0% |
| 2022 | $30.73M | -39.3% |
| 2021 | $50.59M | +220.4% |
| 2020 | $15.79M | -50.7% |
| 2019 | $32.01M | -37.3% |
| 2018 | $51.05M | +65.0% |
| 2017 | $30.95M | +42.2% |
| 2016 | $21.76M | -59.5% |
| 2015 | $53.72M | +2026.8% |
| 2015 | $2.53M | -35.2% |
| 2014 | $3.90M | +710.2% |
| 2014 | $481.0K | -95.1% |
| 2013 | $9.78M | +18.7% |
| 2012 | $8.24M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $243.50M | — | +95.9% |
| July 31, 2025 | $124.30M | +290.3% | -5.6% |
| April 30, 2025 | $131.62M | +314.0% | -21.3% |
| January 31, 2025 | $167.29M | +625.6% | -8.2% |
| December 31, 2024 | $182.33M | — | +338.5% |
| October 31, 2024 | $41.58M | -27.9% | +30.6% |
| July 31, 2024 | $31.85M | -35.5% | +0.2% |
| April 30, 2024 | $31.79M | -43.5% | +37.9% |
- KalVista Pharmaceuticals, Inc. showed an increase of +314.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, KalVista Pharmaceuticals, Inc.’s cash and equivalents has grown by 1496.9% (from $8.24 million to $131.62 million).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: